Kovitz Investment Group Partners LLC trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 83.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,838 shares of the company's stock after selling 40,925 shares during the quarter. Kovitz Investment Group Partners LLC's holdings in Moderna were worth $326,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its holdings in shares of Moderna by 4.2% during the third quarter. Principal Financial Group Inc. now owns 379,451 shares of the company's stock worth $25,359,000 after acquiring an additional 15,218 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Moderna by 31.9% during the 4th quarter. GAMMA Investing LLC now owns 3,173 shares of the company's stock worth $132,000 after purchasing an additional 768 shares in the last quarter. Douglas Lane & Associates LLC raised its stake in shares of Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company's stock valued at $32,175,000 after buying an additional 298,715 shares in the last quarter. Czech National Bank grew its position in Moderna by 6.6% in the fourth quarter. Czech National Bank now owns 73,424 shares of the company's stock valued at $3,053,000 after acquiring an additional 4,526 shares during the period. Finally, Green Alpha Advisors LLC grew its stake in Moderna by 54.9% during the fourth quarter. Green Alpha Advisors LLC now owns 16,900 shares of the company's stock worth $703,000 after buying an additional 5,987 shares during the last quarter. 75.33% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of research analysts have commented on the company. Barclays decreased their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Friday, May 2nd. Evercore ISI cut their price target on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Royal Bank of Canada reduced their price objective on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Bank of America decreased their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Finally, The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and cut their target price for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $53.95.
Check Out Our Latest Stock Report on MRNA
Moderna Stock Performance
Shares of Moderna stock traded up $0.15 during trading on Thursday, hitting $24.21. 3,304,106 shares of the stock were exchanged, compared to its average volume of 7,519,643. The stock has a market cap of $9.36 billion, a PE ratio of -2.61 and a beta of 1.99. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47. The stock's fifty day moving average is $29.13 and its 200 day moving average is $36.98.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same quarter in the previous year, the firm posted ($3.07) earnings per share. Moderna's revenue was down 35.3% compared to the same quarter last year. Sell-side analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current fiscal year.
Moderna Company Profile
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
